ZYNE — Zynerba Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeSmall Cap
- $70.12m
- $34.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.49 | ||
| Price to Tang. Book | 0.49 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -94.34% | ||
| Return on Equity | -70.41% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.09 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders. The Company is engaged in improving the lives of patients and their families living with severe, chronic health conditions, including Fragile X syndrome (FXS), and chromosome 22q11.2 deletion syndrome (22q). It is focused on using cannabinoids for treating behavioral symptoms of FXS and 22q. It is developing Zygel (ZYN002), a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of tetrahydrocannabinol (THC). It uses a patent protected formulation containing ethanol and propylene glycol as solubilizing agents and Transcutol HP as a permeation enhancer. Zygel is an investigational drug product in development for the potential treatment of behavioral symptoms associated with FXS, 22q, and autism spectrum disorder (ASD).
Directors
- Armando Anido CHM (63)
- Terri Sebree PRE (63)
- James Fickenscher CFO (57)
- Suzanne Hanlon VPR (64)
- Brian Rosenberger VBD (52)
- Warren Cooper LED (68)
- John Butler IND (56)
- William Federici IND (61)
- Daniel Kisner IND (74)
- Kenneth Moch IND (66)
- Pamela Stephenson IND (53)
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 31st, 2007
- Public Since
- August 5th, 2015
- No. of Shareholders
- 59
- No. of Employees
- 25
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 53,652,487
- Address
- 80 W. Lancaster Avenue, Suite 300, DEVON, 19333
- Web
- https://www.zynerba.com/
- Phone
- +1 4845817505
- Contact
- Peter Vozzo
- Auditors
- KPMG LLP
Upcoming Events for ZYNE
Q2 2023 Zynerba Pharmaceuticals Inc Earnings Release
Q3 2023 Zynerba Pharmaceuticals Inc Earnings Release
Similar to ZYNE
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Aceragen
NASDAQ Capital Market
Acer Therapeutics
NASDAQ Capital Market
FAQ
What is the Zynerba Pharmaceuticals share price?
As of Today at 01:25 UTC, shares in Zynerba Pharmaceuticals are trading at $0.36. This share price information is delayed by 15 minutes.
How has the Zynerba Pharmaceuticals share price performed this year?
Shares in Zynerba Pharmaceuticals last closed at $0.36 and the price had moved by -70.08% over the past 365 days. In terms of relative price strength the Zynerba Pharmaceuticals share price has underperformed the S&P500 Index by -74.32% over the past year.
What are the analyst and broker recommendations for Zynerba Pharmaceuticals?
The overall consensus recommendation for Zynerba Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Zynerba Pharmaceuticals dividend yield?
Zynerba Pharmaceuticals does not currently pay a dividend.
Does Zynerba Pharmaceuticals pay a dividend?
Zynerba Pharmaceuticals does not currently pay a dividend.
When does Zynerba Pharmaceuticals next pay dividends?
Zynerba Pharmaceuticals does not currently pay a dividend.
How do I buy Zynerba Pharmaceuticals shares?
To buy shares in Zynerba Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Zynerba Pharmaceuticals?
As of the previous close price of $0.36, shares in Zynerba Pharmaceuticals had a market capitalisation of $19.53m.
Where are Zynerba Pharmaceuticals shares listed?
Here are the trading details for Zynerba Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ZYNE
What kind of share is Zynerba Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Zynerba Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Zynerba Pharmaceuticals share price forecast for 2023?
The analyst consensus target price for shares in Zynerba Pharmaceuticals is $5.67. That is 1493.41% above the last closing price of $0.36.
Analysts covering Zynerba Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.76 for the next financial year.
What is the trend in the Zynerba Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Zynerba Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -50%.
As of the last closing price of $0.36, shares in Zynerba Pharmaceuticals were trading -27.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Zynerba Pharmaceuticals PE Ratio?
The Zynerba Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Zynerba Pharmaceuticals?
Zynerba Pharmaceuticals' management team is headed by:
- Armando Anido - CHM
- Terri Sebree - PRE
- James Fickenscher - CFO
- Suzanne Hanlon - VPR
- Brian Rosenberger - VBD
- Warren Cooper - LED
- John Butler - IND
- William Federici - IND
- Daniel Kisner - IND
- Kenneth Moch - IND
- Pamela Stephenson - IND